397 related articles for article (PubMed ID: 35294956)
1. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
Milbury CA; Creeden J; Yip WK; Smith DL; Pattani V; Maxwell K; Sawchyn B; Gjoerup O; Meng W; Skoletsky J; Concepcion AD; Tang Y; Bai X; Dewal N; Ma P; Bailey ST; Thornton J; Pavlick DC; Frampton GM; Lieber D; White J; Burns C; Vietz C
PLoS One; 2022; 17(3):e0264138. PubMed ID: 35294956
[TBL] [Abstract][Full Text] [Related]
2. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
Woodhouse R; Li M; Hughes J; Delfosse D; Skoletsky J; Ma P; Meng W; Dewal N; Milbury C; Clark T; Donahue A; Stover D; Kennedy M; Dacpano-Komansky J; Burns C; Vietz C; Alexander B; Hegde P; Dennis L
PLoS One; 2020; 15(9):e0237802. PubMed ID: 32976510
[TBL] [Abstract][Full Text] [Related]
3. Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
Takeda M; Takahama T; Sakai K; Shimizu S; Watanabe S; Kawakami H; Tanaka K; Sato C; Hayashi H; Nonagase Y; Yonesaka K; Takegawa N; Okuno T; Yoshida T; Fumita S; Suzuki S; Haratani K; Saigoh K; Ito A; Mitsudomi T; Handa H; Fukuoka K; Nakagawa K; Nishio K
Oncologist; 2021 Apr; 26(4):e588-e596. PubMed ID: 33325566
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of StrataNGS, a Multiplex PCR, Semiconductor Sequencing-Based Comprehensive Genomic Profiling Test.
Tomlins SA; Hovelson DH; Harms P; Drewery S; Falkner J; Fischer A; Hipp J; Kwiatkowski K; Lazo de la Vega L; Mitchell K; Reeder T; Siddiqui J; Vakil H; Johnson DB; Rhodes DR
J Mol Diagn; 2021 Nov; 23(11):1515-1533. PubMed ID: 34454112
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
6. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
Wang L; Zhai Q; Lu Q; Lee K; Zheng Q; Hong R; Wang S
Ann Med; 2021 Dec; 53(1):1358-1369. PubMed ID: 34396843
[TBL] [Abstract][Full Text] [Related]
7. Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.
Esposito Abate R; Pasquale R; Sacco A; Simeon V; Maiello MR; Frezzetti D; Chiodini P; Normanno N
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309725
[TBL] [Abstract][Full Text] [Related]
8. Next-Generation Sequencing Concordance Analysis of Comprehensive Solid Tumor Profiling between a Centralized Specialty Laboratory and the Decentralized Personal Genome Diagnostics elio Tissue Complete Kitted Solution.
Deak KL; Jackson JB; Valkenburg KC; Keefer LA; Robinson Gerding KM; Angiuoli SV; Datto MB; McCall SJ
J Mol Diagn; 2021 Oct; 23(10):1324-1333. PubMed ID: 34314880
[TBL] [Abstract][Full Text] [Related]
9. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer.
Kondo T; Matsubara J; Quy PN; Fukuyama K; Nomura M; Funakoshi T; Doi K; Sakamori Y; Yoshioka M; Yokoyama A; Tamaoki M; Kou T; Hirohashi K; Yamada A; Yamamoto Y; Minamiguchi S; Nishigaki M; Yamada T; Kanai M; Matsumoto S; Muto M
Cancer Sci; 2021 Jan; 112(1):296-304. PubMed ID: 33007138
[TBL] [Abstract][Full Text] [Related]
11. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors.
Conroy JM; Pabla S; Glenn ST; Seager RJ; Van Roey E; Gao S; Burgher B; Andreas J; Giamo V; Mallon M; Lee YH; DePietro P; Nesline M; Wang Y; Lenzo FL; Klein R; Zhang S
PLoS One; 2021; 16(12):e0260089. PubMed ID: 34855780
[TBL] [Abstract][Full Text] [Related]
12. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
[TBL] [Abstract][Full Text] [Related]
13. Automated next-generation profiling of genomic alterations in human cancers.
Keefer LA; White JR; Wood DE; Gerding KMR; Valkenburg KC; Riley D; Gault C; Papp E; Vollmer CM; Greer A; Hernandez J; McGregor PM; Zingone A; Ryan BM; Deak K; McCall SJ; Datto MB; Prescott JL; Thompson JF; Cerqueira GC; Jones S; Simmons JK; McElhinny A; Dickey J; Angiuoli SV; Diaz LA; Velculescu VE; Sausen M
Nat Commun; 2022 May; 13(1):2830. PubMed ID: 35595835
[TBL] [Abstract][Full Text] [Related]
14. Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles.
Heilmann AM; Riess JW; McLaughlin-Drubin M; Huang RSP; Hjulstrom M; Creeden J; Alexander BM; Erlich RL
Oncologist; 2024 Feb; 29(2):e224-e236. PubMed ID: 37682776
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Labcorp Plasma Focus Test to Facilitate Precision Oncology Through Cell-Free DNA Genomic Profiling of Solid Tumors.
Verner EL; Jackson JB; Severson E; Valkenburg KC; Greer AE; Riley DR; Sausen M; Maddox C; McGregor PM; Karandikar A; Hastings SB; Previs RA; Reddy VP; Jensen TJ; Ramkissoon SH
J Mol Diagn; 2023 Jul; 25(7):477-489. PubMed ID: 37068734
[TBL] [Abstract][Full Text] [Related]
16. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
[TBL] [Abstract][Full Text] [Related]
17. Analytical validation and clinical utilization of K-4CARE™: a comprehensive genomic profiling assay with personalized MRD detection.
Nguyen Hoang TP; Nguyen TA; Tran NHB; Nguyen Hoang VA; Thi Dao HT; Tran VU; Nguyen YN; Nguyen AT; Nguyen Thi CT; Do Thi TT; Nguyen DS; Nguyen HN; Giang H; Tu LN
Front Mol Biosci; 2024; 11():1334808. PubMed ID: 38404964
[No Abstract] [Full Text] [Related]
18. Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA.
Poh J; Ngeow KC; Pek M; Tan KH; Lim JS; Chen H; Ong CK; Lim JQ; Lim ST; Lim CM; Goh BC; Choudhury Y
PLoS One; 2022; 17(4):e0267389. PubMed ID: 35486650
[TBL] [Abstract][Full Text] [Related]
19. An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing.
Malhotra R; Javle V; Tanwar N; Gowda P; Varghese L; K A; Madhusudhan N; Jaiswal N; K S B; Chatterjee M; Prabhash K; Sreekanthreddy P; Rishi KD; Goswami HM; Veldore VH
Front Oncol; 2023; 13():1002792. PubMed ID: 36994199
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
